Comparative Pharmacology
Head-to-head clinical analysis: ONSOLIS versus TRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONSOLIS versus TRAL.
ONSOLIS vs TRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Onsolis (fentanyl buccal soluble film) is an opioid agonist that binds to mu-opioid receptors in the central nervous system, producing analgesia by increasing potassium conductance and inhibiting calcium channels, leading to reduced neurotransmitter release and hyperpolarization of neurons.
Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.
Onsolis (fentanyl buccal soluble film) is indicated for breakthrough pain in opioid-tolerant patients. The initial dose is 200 mcg placed on the buccal mucosa; titrate to effective dose in 200 mcg increments across subsequent episodes. Maximum frequency: 4 doses per day. Allow at least 2 hours between doses.
10 mg intravenously once daily
None Documented
None Documented
Clinical Note
moderateSertraline + Desmopressin
"The risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin."
Clinical Note
moderateSertraline + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Sertraline."
Clinical Note
moderateSertraline + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Sertraline."
Clinical Note
moderateSertraline + Cyclosporine
Terminal elimination half-life is approximately 3-5 hours in adults, providing sustained analgesic effect with multiple daily dosing.
Terminal elimination half-life is 12–18 hours in patients with normal renal function (CrCl >90 mL/min). In moderate renal impairment (CrCl 30–59 mL/min), half-life extends to 24–36 hours. Clinical context: Dosing interval adjustment required for CrCl <60 mL/min.
Primarily hepatic metabolism via glucuronidation, with approximately 70% of the dose excreted in urine as metabolites and 10-15% in feces as unchanged drug.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion; 30% is eliminated in feces via biliary secretion. Total renal clearance accounts for 85% of systemic clearance.
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The metabolism of Cyclosporine can be decreased when combined with Sertraline."